Company: PRME
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001628280-25-008884
Chunk: 291

Company: Prime Medicine, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 16
Chunk 291
---
, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:Year Ended December 31,20242023Anti-dilutive common stock equivalents:Stock options to purchase common stock11,900,921 7,763,023 Unvested restricted common stock awards3,497,474 4,735,996 Total anti-dilutive common stock equivalents15,398,395 12,499,019 

F-31

Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding:Year Ended December 31, (in thousands, except share and per share data)20242023Numerator:Net loss attributable to common stockholders$(195,882)$(198,133)Denominator:Weighted-average common shares outstanding, basic and diluted118,600,381 90,969,327 Net loss per share attributable to common stockholders, basic and diluted$(1.65)$(2.18)The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of pre-funded warrants sold by the Company to purchase 3,200,005 shares of the Company's common stock. The shares of common stock underlying the pre-funded warrants are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested, and the pre-funded warrants are immediately exercisable upon their issuance date.

11.Income Taxes 

Income tax (benefit) expense consists of the following:Year Ended December 31,(in thousands)20242023Deferred income tax benefit:Federal$— $(279)State— — Total deferred income tax benefit— (279)Total provision (benefit) from income taxes$— $(279)A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:Year Ended December 31,20242023Federal income tax expense at statutory rate21.0 %21.0 %State income taxes, net of federal benefit7.4 %7.3 %Tax credits2.6 %2.0 %Permanent differences(0.9)%(0.9)%Other0.8 %(0.4)%Change in valuation allowance(30.8)%(28.9)%Effective income tax rate— %0.1